Skip to main content

Table 1 Patient characteristics and comparisons between acute cellular rejection (ACR) and no rejection (NR) groups

From: Temporal dynamics of the plasma microbiome in recipients at early post-liver transplantation: a retrospective study

  ACR (n = 13) NR (n = 33) p-value
No. patients (pediatric/adult)a 4/9 8/25 0.72
Age at LT [median (range)]
 Pediatric 13 m (5–50 m) 10.5 m (7–25 m) 0.93
 Adult 39 y (18–63 y) 54 y (24–66 y) 0.02
Sex (male/female) 5/8 11/22 0.74
Living donor/brain death donor 11/2 25/8 0.70
ABO incompatible 3 (23.1%) 4 (12.1%) 0.39
Tacrolimus concentrations (mean ± SD) 7.7 ± 1.5 8.0 ± 1.3 0.59
AST (mean ± SD) b 197 ± 155 235 ± 406 0.75
ALT (mean ± SD) b 409 ± 295 318 ± 366 0.43
Initially treated with mycophenolate mofetil 9 (69.2%) 20 (60.6%) 0.74
Underlying disease
 Biliary atresia 4 (30.8%) 6 (18.2%) 0.44
 Primary sclerosing cholangitis 2 (15.4%) 6 (18.2%) 1.00
 Primary biliary cholangitis 2 (15.4%) 3 (9.1%) 0.61
 Fulminant hepatic failure 1 (7.7%) 4 (12.1%) 1.00
 Hepatitis B 2 (15.4%) 2 (6.1%) 0.57
 Hepatitis C 1 (7.7%) 3 (9.1%) 1.00
 Autoimmune hepatitis 1 (7.7%) 2 (6.1%) 1.00
 Others 2 (15.4%) 7 (21.2%)  
Days of hospitalization after LT [median (range)] 86 (37–208) 59 (24–326) 0.25
  1. NOTE: Data are given as n (%) unless otherwise noted. aOne patient with hepatitis B developed fulminant hepatic failure, and another patient with hepatitis B developed primary biliary cholangitis in the ACR group. bThe peak levels of transaminases observed between days 4 and 14 post-transplantation. P-values were calculated by the Mann–Whitney U test or Fisher’s exact test. LT Liver transplantation, AST Aspartate aminotransferase, ALT Alanine aminotransferase